NCT06441565 2025-07-30
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
Sun Yat-sen University
Phase 2/3 Recruiting
Clinical Trials
12 trialsNCT06280495 2025-05-30
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Phase 2/3 Recruiting
NCT00952029 2020-03-30
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT00647530 2019-05-17
FOxTROT
University of Birmingham
Phase 2/3 Unknown
NCT01646554 2017-05-09
BOS3
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Withdrawn
NCT00384176 2017-04-14
HORIZON III
AstraZeneca
Phase 2/3 Completed
NCT01523431 2017-03-30
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 2/3 Completed
NCT00735241 2015-05-22
FAST
Sirtex Medical
Phase 2/3 Withdrawn
NCT02415699 2015-04-14
DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2/3 Unknown
NCT00975897 2013-12-19
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00284258 2012-11-02
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 2/3 Completed
NCT00274872 2010-02-01
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2/3 Unknown